GCP
QNCX icon

GSA Capital Partners’s Quince Therapeutics QNCX Stock Holding History

GSA Capital Partners’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-560
Closed -$375K – 2084
2025
Q4 		$375K Buy
560
+124
+28% +$62.4K 0.03% 1027
2025
Q3 		$142K Buy
436
+267
+158% +$88.9K 0.01% 1486
2025
Q2 		$56K Sell
169
-14
-8% -$3.2K ﹤0.01% 1657
2025
Q1 		$49K Buy
+183
New +$55.9K ﹤0.01% 1549
2022
Q1 		– Sell
-443
Closed -$1.12M – 1750
2021
Q4 		$1.12M Buy
443
+368
+491% +$2.25M 0.14% 159
2021
Q3 		$1.38M Buy
75
+9
+14% +$143K 0.14% 163
2021
Q2 		$705K Buy
+66
New +$553K 0.08% 415

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

GSA Capital Partners's QNCX Position: Q1 2026 in Review

GSA Capital Partners sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 560 shares — an estimated $375K sold.

GSA Capital Partners first reported a position in QNCX in Q2 2021 and held it in 7 quarters. The position peaked at $1.38M in Q3 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • GSA Capital Partners reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 560 Quince Therapeutics shares in Q1 2026, an estimated $375K.
  • GSA Capital Partners first reported a position in Quince Therapeutics in Q2 2021 and held it in 7 quarters.
  • GSA Capital Partners's Quince Therapeutics position peaked at $1.38M in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.